The hpv vaccine track is experiencing an acute attack, from a “money-printer” to a “red sea”. This is not an ordinary industry fluctuation, but a structural recession triggered by policy-driven, market saturation and increased competition. The most striking test indicator on the diagnostic report is the decline in the “crawling” performance of the head enterprise。
Diagnosis: 10 billion lost from 10 billion camps
The health of the industry is reflected in the financial reports of the two leading firms。
The two “test sheets” point to the same conclusion: the past era of dependence on a single explosive product, high maori, high growth gold, has come to an end。
Diagnosis: policy is external, and vulnerability to business patterns is internal injury
The causes of this “emergency” need to be seen separately from the outside. External factors are policy-driven inclusion, and internal factors are the excessive reliance of enterprises on single-explosion funds and the low risk resistance of business models。
External factors (policy shocks): price systems are “basic-drawn”
In november 2025, double price hpv vaccines were included in the national immunization plan and government procurement became the dominant channel. The aggregate price was as low as 27. 5 yuan/disbursement, representing only 8. 4 per cent of the initial retail price on the market (approximately 329 yuan). This leads directly to:
Professor deng yong, beijing university of chinese medicine, stated that this policy has long served public health well, but in the short term it would allow businesses to enter a situation of “volume price increases”。
Internal factors (structural issues): single pillar, loss and loss
Changes in the external environment are merely a trigger, and the real pathology lies in the industry itself。
Sample analysis: self-help operations in enterprises, effects to be observed
In the face of severe illness, the company is in the process of “surgery” on an emergency basis, with varying results。
However, these transformations face enormous challenges: the number of competitors in the ninth-price markets (boche, rico, watson, etc. Are clinically in stage iii), the weak demand in male markets due to low awareness, and the long approval cycle and limited purchasing power in emerging markets。
Post-pregnancy: structural recession, conditional recovery
The hpv vaccine track has entered a period of structural decline rather than a short cyclical adjustment. Recovery depends on a hierarchy of two conditions:
Condition one: who can find new growth points under the “inclusive” main line
Structural recovery is possible if enterprises succeed in developing:
Condition 2: if caught up in price warfare and homogenization competition, it would lead to long-term micro-benefits。
If firms continue to fight hard on existing tracks, such as nine prices, and are unable to break through these new areas, then the entire industry will be in a long-term state of “a fall in price increases.” enterprises that rely heavily on domestic hpv vaccine operations will face continuing operational pressure。
Final diagnosis: the era of “high growth, high profits” in the hpv vaccine industry is over. It is being transformed into an inclusive, low-profit, competitive public health industry. The future of the enterprise depends no longer on winning the crown of the king of vaccines, but on finding new and sustainable ways of survival in an inclusive era。
